Bachy, Emmanuel
3 papers on CoChatORCID 0000-0003-2694-7510
Most cited papers
- Verified
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Morschhauser, F., Bishton, M., Eyre, T. A., Bachy, E., Cartron, G., Ysebaert, L., Bobillo, S., Gutierrez, N. C., Budde, L. E., Fox, C. P., et al. (2021) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 46
- Verified
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 41
- Verified
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., et al. (2018) · Annals of Hematology
Health Systems, Economic Evaluations, Quality of LifeLymphoma Diagnosis and Treatment
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free